Oxford Biomedica (LON:OXB) Stock Rating Lowered by Deutsche Bank Aktiengesellschaft

Oxford Biomedica (LON:OXB) was downgraded by equities research analysts at Deutsche Bank Aktiengesellschaft to a “hold” rating in a research note issued to investors on Tuesday,Digital Look reports. They currently have a GBX 595 price target on the biopharmaceutical company’s stock, down from their previous price target of GBX 800. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 22.05% from the company’s previous close.

A number of other research firms have also commented on OXB. Royal Bank Of Canada cut their price target on Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating for the company in a report on Monday, August 10th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of GBX 580.85.

Oxford Biomedica Price Performance

Oxford Biomedica stock opened at GBX 487.50 on Tuesday. The business’s 50 day simple moving average is GBX 588.11 and its 200 day simple moving average is GBX 631.69. Oxford Biomedica has a 12 month low of GBX 441.50 and a 12 month high of GBX 952. The company has a market cap of £590.06 million, a price-to-earnings ratio of -18.11 and a beta of 1.10. The company has a current ratio of 2.20, a quick ratio of 1.67 and a debt-to-equity ratio of 162.16.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.